Piper Sandler analyst Biren Amin assumes Monopar Therapeutics (NASDAQ:MNPR) with a Overweight rating and announces Price Target of $76.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
Tencent made a significant acquisition of a 25% stake in Ubisoft's subsidiary, holding popular IPs such as 'Assassin's Creed' and two other major titles.
Last year's biggest dark horse, AppLovin, saw its stock plummet over 20%. The company faced short-selling again, accused of data abuse and violating platform terms.
Tesla's stock price rises against the trend! Analysts indicate that the company will be the big winner from Trump's auto tariffs.
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
Piper Sandler Assumes Monopar Therapeutics at Overweight, Announces Price Target of $76
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 220
Write a comment
Comment(0)
Reason For Report